Company Summary - Summit Corporation PLC (LSE:SUMM)
5.12p
0.12p
(2.40%)
FTSE AIM All Share Pharmaceuticals & BiotechnologyMarket cap: £8.520m
Review a company's summary page in more detail and see the key fundamentals at a glance. Sign-up to Premium now to make your investment decisions.
Sign-up to Premium's Free 7 Day trial See an improved company summary
Summary
The discovery and development of new therapeutics from its iminosugar drug discovery platform in areas of unmet medical need
| Financials - Interim (23/10/2009) | ||
|---|---|---|
| Turnover | £m | 0.11 |
| Pre-tax Profit | £m | -3.13 |
| EPS | p | -7.96 |
| DPS | p | 0.00 |
| Director | Board Role |
|---|---|
| Dr. Barry Price | Chairman |
| Dr. Steven Lee | Chief Executive |
Products Brands & Subsidiaries
Products & Brands
Dextra
Subsidiaries
Dextra Laboratories Ltd; Summit (Oxford) Ltd; Summit (Wales) Ltd; Summit (Cambridge) Ltd; Summit Discovery 2 Ltd...
Broker Sentiment (0 brokers)
No current consensus recommendation available.
| Heading | Date |
|---|---|
| Summit Corporation PLC Director... | 05/03/2010 |
| Summit Corporation PLC Director... | 05/03/2010 |
| Summit Corporation PLC Trading... | 24/02/2010 |
For more information
and investor relations, visit the
Summit Corporation PLC company website: